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Rheumatic heart disease and 
endomyocardial fi brosis: 
Distinguishing the etiology of mitral 
regurgitation in low-resourced areas 
MITRAL VALVE 
DISEASE
Despite these differences, it can be challenging to distinguish 
RHD from left-sided EMF in a clinical context, in particular 
when faced with mitral regurgitation in a low-resource setting. 
Making this distinction correctly is of high value, as the medical 
management, surgical and interventional options, and prognosis 
are considerably different.
Acute EMF vs.  acute RHD
Acute mitral regurgitation can be viewed as part of the acute 
phase of both RHD (acute rheumatic fever, ARF) and EMF. As 
both are clinical diagnoses, lacking a confirmatory test, additional 
diagnostic work-up is needed. Of the 2, the clinical presentation 
of acute rheumatic fever is most clearly defined, and outlined in 
the Jones Criteria.(3) Indeed, in almost all cases, the diagnosis of 
ARF requires evidence of a recent streptococcal infection, as 
the link between untreated or undertreated group A strepto-
coccus (GAS) and ARF is well established. Importantly, the 
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ABSTRACT
INTRODUCTION
Rheumatic heart disease (RHD) and endomyocardial fibrosis 
(EMF) continue to exert a high burden among young popula-
tions living in conditions of poverty. RHD is common in almost 
all low- and middle-income countries, and in some disadvan-
taged populations within high-income countries, such as the 
Aboriginal peoples of Australia. In contrast, EMF is primarily a 
tropical cardiomyopathy, with both high-prevalence countries 
and high-prevalence regions within affected countries. 
While it has been postulated that RHD and EMF are 2 distinct 
expressions of the same pathological process,(1) this is not 
widely believed. In fact, the etiology, pathogenesis, echo-
cardiographic findings, interventions, and prognosis are quite 
distinct. RHD is unarguably the most preventable of all cardiac 
diseases, resulting from untreated or undertreated group A 
streptococcal infections, classically streptococcal pharyngitis, 
which trigger the immunological reaction acute rheumatic 
fever, leading to acute and chronic cardiac damage. After ARF/
RHD is established, penicillin prophylaxis is a powerful modifier 
of disease course, with good adherence leading to stabilisation 
and sometimes regression of disease when initiated early.(2) In 
contrast, attempts to relate EMF to infections, dietary factors 
and toxic agents have failed to unveil the exact etiology and 
pathogenesis, and currently there are no specific drugs to treat 
EMF. Surgery is technically very demanding, and improvement 
in knowledge has been slow. 
Rheumatic heart disease (RHD) and endomyocardial 
fi brosis (EMF) are 2 neglected cardiovascular diseases 
that disproportionately affect young populations, living 
in poverty. RHD characteristically occurs in low- and 
middle-income countries, as well as in some dis-
advantaged populations within high-income countries, 
such as the Aboriginal peoples of Australia. In contrast, 
EMF is primarily a tropical cardiomyopathy, with both 
high-prevalence countries and high-prevalence regions 
within affected countries. 
The etiology, pathogenesis, echocardiographic fi ndings, 
interventions and prognosis are quite distinct. While 
RHD is unarguably the most preventable of all cardiac 
diseases, resulting from untreated or undertreated 
group A streptococcal infections, EMF’s etiology remains 
unclear. It has been related to infections, dietary factors 
and toxic agents, and currently there are no specifi c 
drugs to treat EMF. 
The distinction of mitral lesions due to RHD from left-
sided EMF, can be diffi cult in endemic areas for both 
diseases, especially in the context of lack of resources 
for diagnosis. However, the correct distinction is highly 
important since medical management, surgical and 
interventional options and prognosis are considerably 
different. Here we describe the features that allow this 
distinction in African settings where both diseases occur, 
paying particular emphasis to echocardiography. 
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newest revision of the Jones Criteria(3) allows for echocardio-
graphic evidence of carditis as a major criterion (as opposed 
to previous iterations allowing only auscultation), and provides 
less stringent diagnostic requirements for areas considered to 
be at moderate to high risk, meant to improve the diagnostic 
sensitivity. 
In the setting of ARF, carditis occurs in more than 50% of 
patients, and is predominantly characterised by mitral valvu-
litis.(4) Less often, the aortic valve is also involved with resulting 
aortic regurgitation.(5-7) Rheumatic nodules, or a beaded 
appearance of the mitral leaflet that resolves as inflammation 
subsides, distinguish the mitral valve in ARF from other 
etiologies, but are found in only 25 - 50% of patients with acute 
carditis.(8,9) The mechanism of mitral regurgitation during the 
first episode of ARF is most commonly annular dilation resulting 
from a dilated left ventricle, followed by excessive motion of 
the anterior mitral leaflet caused by chordal elongation 
(inflammation), and in severe cases, chordal rupture. In recurrent 
ARF, the mechanisms are more complex, involving restricted 
leaflet mobility secondary to previous scarring, annular dilation, 
and leaflet prolapse.(9)   
In contrast to ARF, the acute phase of EMF is poorly understood 
and incompletely described. There is no clear consensus on 
EMF’s etiology, with various infectious, nutritional and environ-
mental factors implicated, but not proven. It has been challenging 
to identify patients in the acute phase of disease and the 
majority of those affected are diagnosed in the late stage. Most 
consistently, acute EMF has been characterised by generalised 
allergic/immunological features including fever, abdominal dis-
tension, facial or periorbital swelling, body itching, urticaria, and 
neurological features, and associated with hypereosinophilia 
and myopericarditis.(10) A study in a rural endemic area of 
Mozambique found a prevalence of established EMF at 19.8% in 
the general population; only 22% of participants with echo-
cardiographic features of EMF recalled fever or other complaints 
consistent with acute EMF.(11)
Common to both chronic disease states, is the belief that an 
acute phase exists for the majority of patients and that repeated 
insults (GAS exposure for RHD, unclear for EMF) contribute to 
the chronic cardiac manifestations. Historically, it was believed 
that RHD could not exist without a clear history of ARF, 
however echocardiographic screening studies showing a high 
prevalence of RHD absent history of ARF,(12,13) and the striking 
discrepancy between ARF and RHD burden in low-income 
countries is calling this into question. What is more likely is that 
while some patients exhibit a clear inflammatory state prior to 
development of chronic disease, some also suffer a sub-clinical 
course, presenting only when cardiac manifestations bring them 
to clinical attention.   
PATHOLOGY
The pathological features of the mitral valve in both RHD and 
EMF are distinct and diagnostic, though rarely available in low-
resource settings until post-mortem exam. Aschoff's bodies, 
granulomatous inflammatory nodules, are the histological hall-
mark of acute rheumatic carditis. In chronic RHD, the mitral 
valve is fibrotic and firm, typically with thickening of both leaflets 
seen most prominently at the tips.(14) Additionally, in advanced 
RHD there is thickening of the mitral valve chordal apparatus, 
with shortening and fusion of the chordae, as well as commissural 
fusion. This pathology results in immobility of the posterior 
mitral leaflet and pseudo-prolapse, also known as excessive 
motion of the anterior mitral leaflet.(15) This is notably different 
than classical mitral valve prolapse involving the mid-portion of 
the leaflet body, occurring when the tip of the leaflet extends 
beyond the closure plane during ventricular systole, resulting in 
non-cooptation and mitral regurgitation. Severe mitral annular 
calcification is rare(16) and the ventricular myocardium is grossly 
normal.   
EMF is marked by focal or diffuse areas of endocardial thickening, 
characterised by a white, smooth, and shiny endocardial surface. 
The mitral valve leaflets invariably shows diffused irregular 
thickening, with fibrotic nodules and thickened chordae. The 
posterior leaflet, its chordae and the posterior papillary muscle 
are partially, or totally, fused to the posterior wall.(17,18) The 
anterior papillary muscle may be fused to the wall, with variable 
restriction of its mobility contributing significantly to mitral 
regurgitation and an additional component of mitral stenosis. 
Thrombosis and fibrosis are characteristically prominent in the 
ventricular apex and the posterior wall of the ventricle behind 
the posterior leaflet of the mitral valve. The left ventricular apex 
is frequently scarred and thrombosed, with varying degrees of 
obliteration, but without retraction of the apex. The semilunar 
valves are never involved.(17,18)
CLINICAL AND LABORATORY FEATURES
Though ARF is marked by evidence of group A strep infection 
and elevated inflammatory markers (ESR, CRP), chronic RHD 
has no distinguishing laboratory features. The biological profile 
of chronic EMF is also typically unremarkable, though high 
eosinophil counts are found in a variable proportion of cases.(19) 
Because patients with LEMF do not present the exuberant 
clinical features of chronic right EMF – such as finger clubbing, 
growth retardation, testicular atrophy, failure of the development 
of secondary sexual characters or cachexia - and are usually in 
a better general status, suspicion of LEMF may arise from the 
combination of a typically soft and short systolic murmur 
associated with a delayed opening snap. This is in contrast to 
cardiac auscultation in RHD, which frequently reveals a high-
pitched, blowing and holosystolic apical murmur radiating to 
the axilla. 
Electrocardiography
There are no specific electrical findings that distinguish chronic 
left-sided EMF from chronic RHD. The electrocardiogram in 
both cases reflects the severity of mitral regurgitation and the 
presence and degree of mitral stenosis with variable left 
ventricular and left atrial enlargement as well as a signs of right 
ventricular hypertrophy and strain when significant pulmonary 
hypertension is present. The exception to this is acute rheumatic 
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fever, classically marked by tachycardia and PR prolongation (a 
minor criterion for carditis in the Jones criteria). Wenckebach 
phenomenon and complete heart block are relatively rare.(20)  
Echocardiography
Echocardiography is an essential tool in the diagnosis and 
management of RHD and EMF. Structural and hemodynamic 
abnormalities are important to classify valve lesions in acute 
and chronic phases, as well as to track progression of valve 
abnormalities and help determine the time for surgical inter-
vention.
In rheumatic fever with carditis echocardiography identifies and 
quantifies valve abnormalities, ventricular dysfunction and 
pericardial effusion.(8,21) Acute rheumatic valvulitis is charac-
terised by annular dilatation, elongation of the chordae to the 
anterior leaflet, nodular thickening of valve leaflets and postero-
laterally directed mitral regurgitation jet.(8,9,21) Chordal thickening 
in the context of acute carditis suggests recurrence of acute 
rheumatic fever in patients with established rheumatic heart 
valve disease.(22) Mild mitral regurgitation present during the 
acute phase usually resolves weeks to months after, while 
patients with moderate-to-severe carditis have persistent mitral 
regurgitation. In most cases, the left ventricle is dilated with 
preserved or increased fractional shortening; however, a 
variable degree of ventricular dysfunction may occur in very 
advanced cases in African patients.
Isolated mitral regurgitation is the most common abnormality 
found in chronic RHD(9,21,23) and the most common mor-
phological abnormalities are (a) valve and/or chordal thickening 
(Figure 1a); (b) restrictive leaflet motion due to chordal 
thickening, shortening or fusion, commissural fusion and leaflet 
calcification or thickening (Figure 1b); and (c) chordal elongation, 
rupture or prolapse (Figure 1b).(24-27) The posterior mitral leaflet 
is usually shortened and immobile resulting in non-coaptation 
of the leaflets.(28) Rarely there may be calcification of the 
subvalvar apparatus.(16)
Unique echocardiographic features of mitral regurgitation due 
to LEMF are large endocardial plaques, obliteration of vent-
ricular apices or mitral valve recess, ventricular and atrial 
thrombi, ventricular cavity volume reduction, enlarged atrium, 
restricted mobility of the atrioventricular valve leaflets, fusion of 
the papillary muscles to the wall and abnormalities of the 
ventricular regional wall motion.(29-33) There is usually diffuse 
atrioventricular valve leaflet thickening and abnormal move-
ment of the interventricular septum and/or posterior LV wall.(11) 
On the left side, the ventricular apex is never retracted; it 
becomes thicker leading to considerable reduction of the 
longitudinal diameter of the ventricle, resulting in a spherical 
ventricular shape. These features are shown in Figure 2a. 
Moderate pericardial effusion and endocardial calcification may 
be occasionally found.(34-36) Both the restriction to ventricular 
filling and the atrioventricular valve regurgitation result in an 
increase in atrial pressure, that leads to aneurysmal left atrium 
(Figure 2b). 
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Figure 1A: 2D echocardiogram in apical 4-chamber view in 
a patient with advanced rheumatic heart disease. The left 
atrium (LA) is severely dilated, and the mitral valve leaflets 
demonstrate the characteristic “rolled appearance” at the 
leaflet tips as well as poor leaflet excursion during diastole 
secondary to shortening of the mitral valve chords and mitral 
commissural fusion. 
Figure 1B: 2D echocardiogram in apical 4-chamber view in 
the patient with advanced rheumatic heart disease – now 
during ventricular systole. The white arrow shows the classical 
“excessive motion of the anterior mitral leaflet” that results 
most commonly in advanced RHD from poor mobility of the 
posterior mitral leaflet. Additionally, there is an obvious 
coaptation defect leading to the severe mitral regurgitation 
seen in Figure 1c.
Figure 1C: Colour Doppler 2D echocardiogram in apical 
4-chamber view in the patient with advanced rheumatic heart 
disease – during ventricular systole. The white arrow shows 
the severe mitral regurgitation resulting from mitral leaflet 
non-coaptation.
A
39
20
17
Vo
lu
m
e 
14
 N
um
be
r 1
The restricted movement of the fibrotic left ventricular apex 
and its obliteration are accompanied by compensatory con-
tractile mechanism that results in exaggerated and distinctive 
motion of the basal portion of the left ventricle, the so-called 
Merlon sign.(33,37) On M-mode the interventricular septum 
motion assuming an M-shaped movement, as a result of rapid 
anterior movement in early diastole.(38) 
In early stages of EMF spontaneous contrast and ventricular 
thrombi may be observed in a normally contracting left 
ventricle.(33) Ventricular obliteration – consisting in partial or 
complete exclusion of a portion of the ventricle from the 
circulation – affects both the apex and the recesses of the 
posterior mitral valve leaflet excluding these parts from the 
ventricular cavity.(33) 
The most important echocardiographic features that assist in 
the differential diagnosis of Left-predominant Endomyocardial 
Fibrosis and Rheumatic Mitral Regurgitation. (Table 1)
Other imaging techniques 
Imaging techniques such as axial tomography, magnetic 
resonance imaging and hemodynamic studies with ventri-
culography may complement anatomic and functional informa-
tion in EMF. Computed Tomography, although seldom used in 
endemic areas, may help in depicting morphologic features of 
EMF, by allowing direct visualisation as well as mapping of 
fibrosis in the endocardium and within the myocardial wall. 
The presence of a linear calcification distal to the pericardium 
(along the inner border of the myocardium) suggests EMF at 
conventional and spiral computed tomography.(39) Magnetic 
Resonance Imaging has many advantages for diagnosing LEMF 
as it confirms the existence of thrombus or calcifications, and 
allows an exact delineation of hypoperfused areas that corres-
pond to fibrosis. Advanced imaging is not routinely recom-
mended or useful in the evaluation of patients with RHD, 
though 3-dimentional echocardiography has some incremental 
benefit for surgical planning for mitral valve repair. 
INVASIVE DIAGNOSIS
While cardiac catheterisation can confirm hemodynamic abnor-
malities in EMF patients, it is not routinely recommended as it 
can be misleading in localised or mild forms of the disease and 
technically challenging and dangerous in advanced disease. 
Endomyocardial biopsy is difficult in areas of dense endocardial 
fibrosis and may give false negative results. 
Left-sided EMF is characterised by elevated left ventricular end-
diastolic pressure with dip-plateau pattern. Pulmonary hyper-
tension is variably damped by the presence of the right 
ventricular disease. The left ventricular angiogram shows a 
spherical left ventricle, due to apical obliteration, with varying 
degree of mitral regurgitation.
Cardiac catheterisation is not recommended for routine 
evaluation of patients with RHD, unless the severity and 
reactivity of pulmonary hypertension is in question.  However, 
interventional catheterisation, in the form of mitral balloon 
valvuloplasy, forms a central pillar of treatment for RHD 
patients with mitral stenosis, with an echocardiographic 
Wilcon’s score of ≤8 predicting a favourable outcome with 
percutaneous valvuloplasty and that >8 favouring a surgical 
approach.(40) 
FIGURE 2A: 2D echocardiogram in apical 4-chamber view in a patient with predominant left Endomyocardial Fibrosis. The left ventricle (LV) is 
small. The anterior leaflet of the mitral valve (ALMV) is diffusely thick; the posterior leaflet cannot be seen due to its engulfment in the oblitera-
tion of the posterior mitral recess (O). This fusion of the posterior leaflet to the wall is the basis for non-coaptation and severe mitral regurgitation. 
The left atrium (LA) is aneurysmal while the left ventricle does not present dilatation.
FIGURE 2B: Colour Doppler 2D echocardiogram in apical 4-chamber view in the same patient seen in Figure 2A showing severe mitral 
regurgitation and the aneurysmal left atrium (LA). Also notice the spherical shape of the small left ventricle (LV), with thickened endocardium in 
the apex (TE). 
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SURGICAL MANAGEMENT
RHD surgery is indicated when patients are symptomatic, have 
impairment of left ventricular function and/or severe pulmonary 
arterial hypertension. Because patients with advanced RHD are 
younger in Africa, surgical management is done trying to avoid 
the hazards of lifelong anticoagulation associated with prosthetic 
valves, hence the use of mitral repair. Frequently, the decision 
regarding the type of valve surgery includes not only clinical-
echocardiographic criteria but also the assessment of the 
capacity to adequately follow-up and comply with anti-
coagulation, usually related to economic constrains and, 
sometimes, cultural believes. Mitral valve repair should probably 
be the first choice to maximise survival and reduce morbidity 
associated with valve replacement in young patients and for 
those living in remote areas, even accepting a risk of reoperation. 
Surgery for EMF requires a high level of technical expertise and 
experience. Though high risk, surgery increases survival and 
improves quality of life when compared to medical therapy(32) 
and is indicated in patients in NYHA classes III and IV who have 
structural lesions suitable for correction. Endocardectomy is the 
mainstay of surgical treatment for EMF, allowing relief of 
diastolic dysfunction through the removal of the fibrotic 
endocardium. In most cases, a clearly delineated cleavage plane 
allows for the removal of the stiff endocardium, revealing 
healthy myocardial tissue. Corrective surgery, using subtotal 
ventricular endocardial resection to avoid atrioventricular block, 
atrioventricular valve repair to treat mitral and tricuspid 
incompetence,(41) and new techniques of myocardial protection 
has reduced peri-operative mortality and morbidity. 
PROGNOSIS
In low-resource settings, the tendency of both RHD and EMF 
to be diagnosed in the advanced stage, the lack of cardiology 
expertise, limited resources for medical management, and 
severely restricted or non-existant interventional and surgical 
options, results in poor outcomes for patients with both 
diseases. A recent multinational registry for RHD (REMEDY), 
containing clincial data and outcomes for patients with a new 
diagnosis of RHD, showed a 2-year case fatality rate of 16.9% 
with median age of death only 28.7 years.(42) When ideal 
medical and interventional therapy is availible, outcomes for 
RHD are much improved, with the majority of mortality related 
to compliance with secondary prophylaxis (lifetime for those 
requiring surgery), and complications of anticoagulation in those 
with mechanical mitral valves. Outcomes for patients with EMF, 
regardless of access to high-quality medical care, are substantially 
worse, though improving with strategies aimed at controlling 
heart failure symptoms, avoiding or treating arrythmias, and a 
push towards earlier surgical intervention.(41) Currently, endo-
cardial resection with atrioventricular valve replacement has a 
reported 70% 10-year survival.(43) 
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TABLE 1: Distinguishing features to differentiate patients with 
rheumatic mitral regurgitation from those with left-dominant endo-
myocardial fibrosis.
AI = aortic valve, AV = aortic valve, ARF = acute rheumatic fever, 
ECG = electrocardiogram, GAS = group A streptococcus, LA = left atrium, 
LV = left ventricle, MR = mitral regurgitation, MV = mitral valve, PR = PR interval.
Acute Phase
Pathology
Clinical
Laboratory
ECG
Echocardiography
Rheumatic Heart 
Disease
Acute Rheumatic Fever, 
Evidence of recent GAS 
infection, PR 
prolongation on ECG
ARF:  Ashoff bodies
Chronic RHD:  fi brotic, 
thickened MV, posterior 
leafl et immobility, 
chordal thickening and 
commissural fusion, 
normal endocardium 
High-pitched, blowing, 
holosystolic apical 
murmur, radiating to the 
axilla
ARF:  evidence of GAS 
and elevated 
infl ammatory markers
Chronic RHD: None
ARF:  tachycardia, 
prolonged PR
Chronic RHD:  No 
specifi c features
Morphological 
(thickened MV, “elbow 
deformity”, restricted 
posterior mitral leafl et, 
chordal thickening) and 
Functional MV disease 
(MR +/- MS), with 
concurrent AV 
involvement (typically 
AI) in ≈ 20% patients, 
normal endocardium, 
typically with normal LV 
function in all but the 
most severe cases
Endomyocardial 
Fibrosis
Generalised Allergic/
Immune features:  facial/
periorbital swelling, 
itching, urticaria, 
abdominal distension
Focal or diffuse areas of 
endocardial thickening 
(white, smooth, shiny 
endocardial plaques), 
posterior mitral leafl et 
fused to LV free wall 
+/- anterior mitral leafl et 
fused to septal wall, 
thrombosis/fi brosis of LV 
apex with LV apical 
obliteration at later 
stages
Soft, short systolic 
murmur with a delayed 
opening snap
Variable presentation 
with eosinophilia
EMF:  No specifi c 
features
Bright endocardial 
plaques; Plastered 
posterior mitral leafl et, 
sometimes completely 
adherent to the wall; 
Spherical  left ventricle 
due to reduced 
longitudinal dimension; 
Obliterated left 
ventricular apex or 
posterior papillary 
muscle recess;   LV apical 
thrombus; Endocardial 
calcifi cation of the apex 
of the left ventricle; 
Spontaneous contrast or 
intra-cavitary thrombi;  
M-movement of 
interventricular septum 
and/or posterior wall; LA 
dilation out of 
proportion to MR 
(aneurysmal LA) and 
sometimes with 
pericardial effusion
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